Insider Transactions in Q3 2025 at Fennec Pharmaceuticals Inc. (FENC)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,430
+1.4%
|
-
|
|
Sep 30
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+5.33%
|
-
|
|
Sep 05
2025
|
Rosty Raykov |
BUY
Exercise of conversion of derivative security
|
Direct |
36,207
+29.32%
|
$72,414
$2.45 P/Share
|
|
Sep 04
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-16.37%
|
$80,000
$8.92 P/Share
|
|
Aug 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+7.86%
|
-
|
|
Aug 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.42%
|
-
|
|
Aug 05
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-15.18%
|
$80,000
$8.09 P/Share
|
|
Jul 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.44%
|
-
|
|
Jul 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+7.33%
|
-
|
|
Jul 07
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,119
-2.0%
|
$8,952
$8.71 P/Share
|
|
Jul 07
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,127
+3.66%
|
$4,254
$2.35 P/Share
|
|
Jul 03
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-14.15%
|
$80,000
$8.61 P/Share
|